Physician profile
Mark A Operario
NPI 1720099344
$492.51
in general payments reported to CMS, 2019-2025
11 companies · $75.60 in 2025
The $75.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.58 · 2020: $50.85 · 2021: $68.78 · 2022: $13.50 · 2023: $232 · 2025: $75.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261 · Education: $46.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.98 |
| Education | $46.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $176.89 | 2023 | |
| Abbvie INC. | $78.93 | 2021-2025 | |
| Lilly USA, LLC | $46.56 | 2020-2023 | |
| Pfizer INC. | $38.61 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $38.38 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $35.51 | 2019-2020 | |
| Viatris Specialty LLC | $23.32 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.85 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.71 | 2020 | |
| Abbott Laboratories | $13.50 | 2022 | |
| Circassia INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Operario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.